Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...
Johnson & Johnson and Merck & Co. are cutting jobs in China, as they face growing competition from domestic rivals resulting ...
Seeking Alpha on MSN20h
Incyte seesaws on report of potential Merck takeover interestIncyte (NASDAQ:INCY) shares seesawed and are now down 10% amid a posting about potential takeover speculation from Merck ...
Shares of Merck & Co. Inc. MRK dropped 0.02% to $96.54 Tuesday, on what proved to be an all-around mixed trading session ...
Warren Buffett was a net seller of stocks for the eighth consecutive quarter in Q3. Berkshire initiated new positions in only ...
Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield ...
Merck (MRK) declared a quarterly dividend of 81c per share of the company’s common stock for Q1 of 2025. Payment will be made on January 8, ...
On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...
The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...
Mark Kleinman, Sky News’ City editor, posted on X, the service formerly known as Twitter: “Revealed: Merck (MRK), the US-listed pharma group, ...
In addition to the Phase 3 MK-3475A-D77 trial, Merck’s subcutaneous pembrolizumab clinical development program includes the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback